spacer
home > pmps > winter 2003 > pharmaceutical manufacturing now a contracting business proposition?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Pharmaceutical Manufacturing now a Contracting Business Proposition?

As the sector reaches a stage of maturity in a turbulent and highly competitive marketplace, quality issues dominate the agenda - or are things not quite what they seem at first glance?

The annual conference for contract manufacturing sponsored by Analysis and Networking came home to central London on 19th-20th November 2003. In a turbulent climate for manufacturing generally, that this meeting happened to coincide with the first ever state visit of a US President to the UK, amid the tightest security the capital has ever seen, made it an historic occasion. It was also an excellent opportunity to reflect on the last 10 years of an evolving contract pharmaceutical manufacturing business sector, whilst looking forward to what the future holds in a rapidly changing marketplace. Where the 7th annual conference in Madrid in November 2002 sparked a gladiatorial debate around the twin issues of quality and price, the argument in favour of quality as the number one priority brought it to the top of the London agenda (1). Delia Rumpf, Programme Manager, opened the conference with an interesting survey of senior executives from both pharma companies and contract manufacturers as well as some management consultants, reflecting delegates' expectations of the meeting.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Charles E Horth, Life Science Consulting Editor

Dr Charles Horth is Life Science Consulting Editor at Cytops, UK. Having gained a PhD in Biochemical Pharmacology, Charles has spent over 30 years in the life science industry after training in biochemistry, medical biochemistry and physiology. His industrial career began with market research in biotechnology, followed by laboratory instrument development. He subsequently worked for Vitamins Research (now part of GSK), CIBA-Geigy in Basel, Switzerland (now Novartis) and Searle, UK (now Pharmacia/Pfizer). Charles helped to set up and market a contract laboratory service for bioanalytical testing, metabolism studies, diagnostics and clinical development services. Charles provides professional advisory services for the pharma, biotech and nutraceuticals sector for a number of European clients. He writes for biotech and pharma publications, has published over 40 scientific articles and was Managing Editor of BioPharmaWeb at VerticalNet Europe and Editor of Life Science Today.


spacer
Dr Charles Horth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement